Skip to content

A Human Versus Machine Comparison Study

A Step Towards Fully Automated Adaptive Radiotherapy in Head & Neck Cancer: A Human Versus Machine Comparison Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06035653
Acronym
HuVeM
Enrollment
40
Registered
2023-09-13
Start date
2023-04-03
Completion date
2023-11-27
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Brief summary

The study aims to retrospectively, and anonymously analyse the data of patients treated over a period of 12 months. These are the patients whose radiotherapy plan were needed to be reviewed in the weekly on-treatment head and neck multi-professional radiotherapy meeting during the course of their radiation. Collected clinical data will be included in the retrospective analysis, comparing the clinical decision (gold standard of care), against the predictive capability of intelligence software

Detailed description

This is a single centre, non-interventional study comparing machine against clinician's standard of care approach. The utilisation of intelligence software is for research purposes only and does not permit active changes to patients' clinical management. Any software related analyses will be done after patients have completed radiation treatment. All consented patients who were discussed in the head and neck CBCT meeting and deemed to require new masks / recontouring / replanning - Cohort A will be analysed on completion of radiotherapy. These patients typically are ones with nodal disease of \>3cm at presentation, and whose weight change is notable 5 - 10% of baseline in the first 2 weeks of their treatment. There have been 28 patients in 12 months previously. Other patients discussed in the head and neck CBCT meeting on completion of radiation - Cohort B, whose radiotherapy was not deemed to require total replan but were clinically deemed 'marginal' will be included. These patients tend to be ones with weight loss measuring close to 1.29cm lateral separation or between the skin surface and the head shell. The radiotherapy replan volumes CTVs of Cohort A patients will retrospectively compared to the CTVs produced by the intelligence software. The time using the software to produce dynamic CTVs will be compared with the time needed for the clinicians to create new CTV for the radiotherapy replan, which will be recorded prospectively. The CBCTs of both Cohorts A & B will be analysed using the intelligence software to determine the adequacy of PTV coverage. This is to be compared with the departmental quality assurance/audit of PTV margins. The software will also be used to calculate various aspects of the radiotherapy plans, including the cumulative dose distribution over the period of dynamic anatomical change Cohorts A & B.

Interventions

None listed

Sponsors

East and North Hertfordshire NHS Trust
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* i. Head and neck cancer patients who require new mask for radiotherapy replanning will be included (Cohort A). These patients typically are ones with rapid shrinkage of the nodal disease, or whose weight change is notable (5 - 10% of baseline) in the first 2 weeks of radiotherapy ii. Patients on close observation of the head and neck multi-professional team but whose radiotherapy did no undergo total replan treatment will be included (Cohort B)

Exclusion criteria

i. Patients whose primary malignancy is not of head and neck origin ii. Patients who specifically opt against their information be used anonymously iii. Head and neck cancer patients whose radiotherapy plans did not require review in the head and neck multi-professional radiotherapy meeting iv. Patients under the age of 18

Design outcomes

Primary

MeasureTime frameDescription
PTV margins compared against the departmental standards1 yearProportion of clinical tumour volume covered by different radiotherapy set up margins 3, 4 and 5mm
Interobserver variability studies (IOV) between manually contoured CTVs and software-generated deformed CTVs - Geographical miss index1 yearMeasurement of under contouring
Interobserver variability studies (IOV) between manually contoured CTVs and software-generated deformed CTVs - Hausdorff distance1 yearMeasurement of distance between 2 volumes
Interobserver variability studies (IOV) between manually contoured CTVs and software-generated deformed CTVs1 yearMeasured by volume differences
Interobserver variability studies (IOV) between manually contoured CTVs and software-generated deformed CTVs - Sorensen-DICE Coefficient1 yearMeasurement of ratio of overlap
Interobserver variability studies (IOV) between manually contoured CTVs and software-generated deformed CTVs - Discordance Index1 yearMeasurement of over contouring

Secondary

MeasureTime frameDescription
Evaluation of clinical decision on total radiotherapy re-plan1 yearMeasured by retrospective assessment of dose accumulation of the CTVs
Potential time saved recontouring with software and the associated cost of re-planning adaptive radiotherapy1 yearDifference between time spent on re- contouring and time spent on editing software deformed CTVs

Countries

United Kingdom

Contacts

Primary ContactKevin Chiu
k.chiu@nhs.net0203 826 2020
Backup ContactRishma Bhatti
mvccresearch.enh-tr@nhs.net0203 826 2020

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026